Skip to main content
. 2023 Aug 4;8(10):2017–2028. doi: 10.1016/j.ekir.2023.07.022

Figure 4.

Figure 4

This figure illustrates the chronic eGFR slope in CR versus non-CR patients for (a) the entire time period on sparsentan treatment and (b) at year 2 of sparsentan treatment. Chronic slope was analyzed using a random coefficients model with linear spline at 42 days. Slope estimates within the non-CR group: P < 0.001 (a and b). Slope estimates within the CR group: (a) P = 0.226 and (b) P = 0.726. CR, complete remission; eGFR, estimated glomerular filtration rate.